Test Price
600 AED✅ Home Collection Available
GATA-3 Immunohistochemistry (IHC) Test in UAE | 600 AED | Precision Cancer Subtyping
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited immunohistochemistry processing. Turnaround Time: 5–7 working days from specimen receipt. Sample Type: FFPE tissue block or biopsy tissue in 10% formalin. Price: 600 AED inclusive of telephonic post-test clinical guidance. DHA Facility License: 1143. Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Collection Logistics: Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
Test Overview & Methodology
The GATA-3 immunohistochemistry test detects GATA binding protein 3 expression in tumor tissue using a monoclonal antibody (clone L50-823). This assay is essential for classifying breast and urothelial carcinomas, supporting oncologists in distinguishing primary tumor origins and selecting targeted therapeutic pathways. The test is performed on formalin-fixed, paraffin-embedded (FFPE) tissue sections using ISO 9001:2015 accredited IHC staining protocols on automated platforms.
Pre-test requirements: Provide a copy of the histopathology report, biopsy site details, and clinical history. Submit tumor tissue in 10% formal-saline OR a formalin-fixed paraffin-embedded block; ship at ambient temperature via secure medical courier.
| Feature | Our GATA-3 IHC Test | Closest Alternative (General IHC Panel) |
|---|---|---|
| Precision & Method | Monoclonal GATA-3 antibody (clone L50-823), ISO‑accredited IHC on automated platform | Polyclonal or non‑specific markers with lower diagnostic accuracy |
| Turnaround Time | FFPE block: 5 days; Tissue biopsy: 5 days; Large complex: 7 days | Usually 7–10 working days |
| Post‑Test Guidance | Telephonic clinical consultation included with results | Limited or no interpretive support provided |
Physician Insight & Safety Protocols
“As a Specialist Diagnostic Radiology professional reviewing GATA-3 IHC results, I emphasise that positive GATA-3 expression strongly suggests breast or urothelial origin. However, definitive diagnosis must integrate morphological features, complementary immunohistochemical markers (e.g., ER, PR, HER2, CK7, CK20), and full clinical and radiographic context. Always correlate these findings with your treating oncologist to personalise management. This single marker does not replace comprehensive tumour profiling.” — Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
Advisory: Medication & Clinical Management
⚠ Do not discontinue prescribed medications without consulting your doctor. Abrupt changes in therapy may lead to adverse outcomes. Some anticoagulant or antiplatelet agents may require temporary adjustment only under the explicit guidance of the performing physician. Always inform your healthcare team of all current medications and supplements prior to biopsy.
Exclusion Criteria & Emergency Red Flags
- Patients under 18 years of age without legal guardian consent per Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Inadequate tissue sample or unconfirmed biopsy site provenance.
- Sample submitted without accompanying histopathology report or documented clinical history.
Seek immediate emergency care if you experience:
- Uncontrolled bleeding from the biopsy site.
- Rapid growth of a lump or appearance of a new mass.
- Severe unexplained pain or systemic symptoms such as fever or shortness of breath.
Patient FAQ & Clinical Guidance
1. What does a positive GATA-3 result indicate?
A positive GATA-3 result suggests the tumour likely originated from breast or urothelial tissue. This biomarker assists oncologists in differentiating carcinoma subtypes and selecting targeted therapies. In breast cancer, GATA-3 positivity correlates with luminal subtypes; in bladder cancer, it supports urothelial origin. These findings must always be interpreted alongside full histopathology and imaging data.
2. How is the sample collected for GATA-3 testing?
A surgeon or interventional radiologist obtains a small tumour tissue sample via needle core biopsy or open surgical biopsy. The specimen is immediately placed in 10% neutral buffered formalin to preserve antigenicity. At DNA Labs UAE, the fixed tissue is embedded in a paraffin block, sectioned, and stained using the monoclonal GATA-3 antibody (clone L50-823). The FFPE block is transported at ambient temperature via a secure medical courier system.
3. Will I need to stop any medications before the biopsy?
Do not discontinue any prescribed medication without explicit instruction from your physician. Certain blood thinners (anticoagulants or antiplatelet agents) may require temporary adjustment, but only under the direction of the performing clinician. Provide a complete list of all medications, including over-the-counter drugs and herbal supplements, to your healthcare team before the procedure.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under DHA Facility License Number 1143 and strictly complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient data, including immunohistochemistry results and clinical records, are processed with industry-standard encryption, access controls, and audit logging. Informed consent for tissue testing and data handling is obtained in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability. No patient information is shared with third parties without explicit written authorisation.
Clinical & Logistical Metadata
| Test Name | GATA-3 Immunohistochemistry (IHC) – Monoclonal Antibody (clone L50-823) |
| Price (AED) | 600 AED (includes telephonic post-test clinical guidance) |
| Turnaround Time | 5–7 working days from receipt of FFPE block or fixed tissue |
| Sample Type / Matrix | FFPE tissue block OR biopsy tissue fixed in 10% formal-saline (hospital extraction only; home collection disabled for safety) |
| Methodology Used | Monoclonal GATA-3 antibody (clone L50-823), ISO 9001:2015 accredited IHC on automated staining platform, DAB chromogen detection |
| ICD-10-CM Code | C50.9 (Malignant neoplasm of breast, unspecified); C67.9 (Malignant neoplasm of bladder, unspecified) |
| LOINC Code | 104217-0 (GATA3 [Presence] in Tissue by Immunohistochemistry) |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians